Press Releases Calliditas Therapeutics AB Nasdaq

Equities

CALT

US13124Q1067

Market Closed - Nasdaq Other stock markets 21:30:00 17/06/2024 BST			5-day change	1st Jan Change
38.95 ^USD	+0.47%		-1.39%	+51.31%

01:05pm	Calliditas Therapeutics Secures US Patent for Cancer Treatment Inhibitor	MT
06-07	European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading	MT

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Calliditas provides setanaxib patent update	11:16am	AQ
Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)	06-17	AQ
Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo[®] for the treatment of IgA nephropathy	05-30	AQ
CALT STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Calliditas Therapeutics AB Is Fair to Shareholders	05-28	BU
Calliditas Therapeutics Presents Data at the 61[st] European Renal Association Congress	05-28	AQ
Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei Corporation	05-28	AQ
Calliditas Therapeutics : May 23, 2024 Interim Report Q1 2024 (Presentation)	05-23	PU
Calliditas Therapeutics : May 23, 2024 Interim Report Q1 2024 (Report)	05-23	PU
Calliditas Q1 report, January - March 2024	05-23	AQ
In Person & Virtual R&D Day: The Anti Fibrotic Effects of Setanaxib and TARPEYO's Mode of Action	05-16	PU
In-Person & Virtual R&D Day: The Anti-Fibrotic Effects of Setanaxib and TARPEYO's Mode of Action	05-16	AQ
Calliditas Therapeutics : Invitation to the presentation of Calliditas´s interim report January - March 2024	05-16	PU
Invitation to the presentation of Calliditas's interim report January - March 2024	05-16	AQ
Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in Stockholm	05-15	AQ
Notice of annual general meeting of Calliditas Therapeutics AB (publ)	05-15	AQ
Calliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in China	05-14	AQ
Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib	05-06	AQ
Calliditas Therapeutics' 2023 Annual Report Published	04-24	AQ
Calliditas Announces Positive NefIgArd Open Label Extension Results	04-24	AQ
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024	04-18	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Calliditas Therapeutics AB Nasdaq

Equities

CALT

US13124Q1067

Press Releases

Filters